^
Association details:
| Biomarker: | ALK R1275Q |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
Published date:
05/05/2023
Excerpt:
Patient 3 harbored a germline ALK R1275Q mutation that remained stable at the expected 50% VAF, with complete response to lorlatinib….These data allow the elucidation of mechanisms of response and resistance to ALK inhibition with lorlatinib in patients with relapsed/refractory ALK-mutated neuroblastoma...
DOI:
https://doi.org/10.1038/s41467-023-38195-0
